Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Dyslipidemia

  Free Subscription


Articles published in Atherosclerosis

Retrieve available abstracts of 165 articles:
HTML format



Single Articles


    October 2021
  1. AHMED AI, Han Y, Al Rifai M, Alnabelsi T, et al
    Added prognostic value of plaque burden to computed tomography angiography and myocardial perfusion imaging.
    Atherosclerosis. 2021;334:9-16.
    PubMed     Abstract available


    September 2021
  2. PAQUETTE M, Bernard S, Baass A
    Hemoglobin concentration, hematocrit and red blood cell count predict major adverse cardiovascular events in patients with familial hypercholesterolemia.
    Atherosclerosis. 2021;335:41-46.
    PubMed     Abstract available


  3. KLEVMOEN M, Bogsrud MP, Retterstol K, Svilaas T, et al
    Loss of statin treatment years during pregnancy and breastfeeding periods in women with familial hypercholesterolemia.
    Atherosclerosis. 2021;335:8-15.
    PubMed     Abstract available


  4. KOSUGI T, Eriguchi M, Yoshida H, Tasaki H, et al
    Association between chronic kidney disease and new-onset dyslipidemia: The Japan Specific Health Checkups (J-SHC) study.
    Atherosclerosis. 2021;332:24-32.
    PubMed     Abstract available


    August 2021
  5. DYRBUS K, Gasior M, Desperak P, Trzeciak P, et al
    Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry.
    Atherosclerosis. 2021;333:16-23.
    PubMed     Abstract available


  6. TOMBLING BJ, Zhang Y, Huang YH, Craik DJ, et al
    The emerging landscape of peptide-based inhibitors of PCSK9.
    Atherosclerosis. 2021;330:52-60.
    PubMed     Abstract available


    July 2021
  7. KATZMANN JL, Lehmann M, Tunnemann-Tarr A, An Haack I, et al
    Cutaneous manifestations in familial hypercholesterolaemia.
    Atherosclerosis. 2021 Jul 11. pii: S0021-9150(21)01236.
    PubMed     Abstract available


  8. KHALIL YA, Rabes JP, Boileau C, Varret M, et al
    APOE gene variants in primary dyslipidemia.
    Atherosclerosis. 2021;328:11-22.
    PubMed     Abstract available


  9. ALVES AC, Azevedo S, Benito-Vicente A, Graca R, et al
    LDLR variants functional characterization: Contribution to variant classification.
    Atherosclerosis. 2021;329:14-21.
    PubMed     Abstract available


    June 2021
  10. MALO AI, Girona J, Ibarretxe D, Rodriguez-Borjabad C, et al
    Serum glycoproteins A and B assessed by (1)H-NMR in familial hypercholesterolemia.
    Atherosclerosis. 2021;330:1-7.
    PubMed     Abstract available


  11. PAQUETTE M, Fantino M, Bernard S, Baass A, et al
    Paternal inheritance predicts earlier cardiovascular event onset in patients with familial hypercholesterolemia.
    Atherosclerosis. 2021;329:9-13.
    PubMed     Abstract available


    May 2021
  12. REESKAMP LF, Nurmohamed NS, Bom MJ, Planken RN, et al
    Marked plaque regression in homozygous familial hypercholesterolemia.
    Atherosclerosis. 2021;327:13-17.
    PubMed     Abstract available


  13. HEIDEMANN BE, Wolters FJ, Kavousi M, Gruppen EG, et al
    Adiposity and the development of dyslipidemia in APOE epsilon2 homozygous subjects: A longitudinal analysis in two population-based cohorts.
    Atherosclerosis. 2021;325:57-62.
    PubMed     Abstract available


  14. LEE JH, Lee HS, Cho AR, Lee YJ, et al
    Relationship between muscle mass index and LDL cholesterol target levels: Analysis of two studies of the Korean population.
    Atherosclerosis. 2021;325:1-7.
    PubMed     Abstract available


    April 2021
  15. BRANDTS J, Dharmayat KI, Vallejo-Vaz AJ, Azar Sharabiani MT, et al
    A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia.
    Atherosclerosis. 2021;325:46-56.
    PubMed     Abstract available


  16. INGOE L, Potter A, Musson S, Neely D, et al
    Improving the identification of patients with a genetic diagnosis of familial hypercholesterolaemia in primary care: A strategy to achieve the NHS long term plan.
    Atherosclerosis. 2021;325:38-45.
    PubMed     Abstract available


  17. SUADONI MT
    Benefits and harms of LDL-cholesterol-lowering therapy in older people must be established through valid and clinically relevant evidence.
    Atherosclerosis. 2021;323:57-58.
    PubMed    


  18. ZAFEIROPOULOS S, Farmakis I, Kartas A, Arvanitaki A, et al
    Reinforcing adherence to lipid-lowering therapy after an acute coronary syndrome: A pragmatic randomized controlled trial.
    Atherosclerosis. 2021;323:37-43.
    PubMed     Abstract available


  19. LIMA JG, Helena C Nobrega L, Moura Bandeira FT, Pires Sousa AG, et al
    A novel GPIHBP1 mutation related to familial chylomicronemia syndrome: A series of cases.
    Atherosclerosis. 2021;322:31-38.
    PubMed     Abstract available


  20. JO SH, Han SH, Kim SH, Eckel RH, et al
    Cardiovascular effects of omega-3 fatty acids: Hope or hype?
    Atherosclerosis. 2021;322:15-23.
    PubMed     Abstract available


    March 2021
  21. BUONUOMO PS, Mastrogiorgio G, Leone G, Rana I, et al
    Evolocumab in the management of children <10 years of age affected by homozygous familial hypercholesterolemia.
    Atherosclerosis. 2021 Mar 28. pii: S0021-9150(21)00147.
    PubMed    


  22. ELLINS EA, Watkins S, Rees DA, Datta DBN, et al
    Acute effect of a single session of lipoprotein apheresis on central haemodynamics in patients with familial hypercholesterolaemia.
    Atherosclerosis. 2021 Mar 27. pii: S0021-9150(21)00144.
    PubMed    


  23. BIESECKER LG
    Correspondence on: "Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features".
    Atherosclerosis. 2021 Mar 20. pii: S0021-9150(21)00125.
    PubMed    


  24. BANACH M, Penson PE
    Lipid-lowering therapies: Better together.
    Atherosclerosis. 2021;320:86-88.
    PubMed    


    February 2021
  25. LEREN TP, Bogsrud MP
    Molecular genetic testing for autosomal dominant hypercholesterolemia in 29,449 Norwegian index patients and 14,230 relatives during the years 1993-2020.
    Atherosclerosis. 2021;322:61-66.
    PubMed     Abstract available


  26. REESKAMP LF, Balvers M, Peter J, van de Kerkhof L, et al
    Intronic variant screening with targeted next-generation sequencing reveals first pseudoexon in LDLR in familial hypercholesterolemia.
    Atherosclerosis. 2021;321:14-20.
    PubMed     Abstract available


    January 2021
  27. VUORIO A, Raal F, Kaste M, Kovanen PT, et al
    Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment.
    Atherosclerosis. 2021;320:53-60.
    PubMed     Abstract available


  28. MARCO-BENEDI V, Laclaustra M, Bea AM, Suarez-Tembra M, et al
    Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia.
    Atherosclerosis. 2021;320:47-52.
    PubMed     Abstract available


  29. FUTEMA M, Ramaswami U, Tichy L, Bogsrud MP, et al
    Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.
    Atherosclerosis. 2021;319:108-117.
    PubMed     Abstract available


  30. VALLEJO-VAZ AJ, Packard CJ, Ference BA, Santos RD, et al
    LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial.
    Atherosclerosis. 2021;320:1-9.
    PubMed     Abstract available


  31. KOROSOGLOU G, Chatzizisis YS, Raggi P
    Coronary computed tomography angiography in asymptomatic patients: Still a taboo or precision medicine?
    Atherosclerosis. 2021;317:47-49.
    PubMed    


  32. STOCK JK
    Should we treat high LDL cholesterol in 'healthy' elderly individuals?
    Atherosclerosis. 2021;317:50-51.
    PubMed    


    December 2020
  33. RUBINO J, MacDougall DE, Sterling LR, Hanselman JC, et al
    Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial.
    Atherosclerosis. 2020 Dec 31. pii: S0021-9150(20)31597.
    PubMed     Abstract available


  34. SVENDSEN K, Krogh HW, Igland J, Tell GS, et al
    2.5-fold increased risk of recurrent acute myocardial infarction with familial hypercholesterolemia.
    Atherosclerosis. 2020;319:28-34.
    PubMed     Abstract available


  35. COUTINHO ER, Miname MH, Rocha VZ, Bittencourt MS, et al
    Familial hypercholesterolemia and cardiovascular disease in older individuals.
    Atherosclerosis. 2020;318:32-37.
    PubMed     Abstract available


  36. SVENDSEN K, Langslet G, Krogh HW, Brinck J, et al
    Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: Examples from Scandinavia.
    Atherosclerosis. 2020;316:48-52.
    PubMed     Abstract available


    November 2020
  37. PEREZ DE ISLA L, Alonso R, Gomez de Diego JJ, Muniz-Grijalvo O, et al
    Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study.
    Atherosclerosis. 2020 Nov 18. pii: S0021-9150(20)31521.
    PubMed     Abstract available


  38. REESKAMP LF, Tromp TR, Huijgen R, Stroes ESG, et al
    Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation.
    Atherosclerosis. 2020;315:68-75.
    PubMed     Abstract available


    October 2020
  39. IYEN B, Qureshi N, Weng S, Roderick P, et al
    Sex differences in cardiovascular morbidity associated with familial hypercholesterolaemia: A retrospective cohort study of the UK Simon Broome register linked to national hospital records.
    Atherosclerosis. 2020 Oct 31. pii: S0021-9150(20)31491.
    PubMed     Abstract available


    September 2020
  40. IQBAL Z, Ho JH, Adam S, France M, et al
    Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK.
    Atherosclerosis. 2020;313:126-136.
    PubMed     Abstract available


  41. BERTOLINI S, Calandra S, Arca M, Averna M, et al
    Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features.
    Atherosclerosis. 2020;312:72-78.
    PubMed     Abstract available


    August 2020
  42. RODRIGUEZ-NOVOA S, Rodriguez-Jimenez C, Alonso C, Rodriguez-Laguna L, et al
    Familial hypercholesterolemia: A single-nucleotide variant (SNV) in mosaic at the low density lipoprotein receptor (LDLR).
    Atherosclerosis. 2020;311:37-43.
    PubMed     Abstract available


  43. PEPPLINKHUIZEN S, Ibrahim S, Vink R, Groot B, et al
    Electronic health records to facilitate continuous detection of familial hypercholesterolemia.
    Atherosclerosis. 2020;310:83-87.
    PubMed     Abstract available


  44. ALJENEDIL S, Alothman L, Belanger AM, Brown L, et al
    Lomitapide for treatment of homozygous familial hypercholesterolemia: The Quebec experience.
    Atherosclerosis. 2020;310:54-63.
    PubMed     Abstract available


    July 2020
  45. RALLIDIS LS, Liberopoulos EN, Vlachopoulos C, Skoumas I, et al
    Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors.
    Atherosclerosis. 2020 Jul 30. pii: S0021-9150(20)30385.
    PubMed    


  46. FUKUMOTO K, Takemoto Y, Yoshikawa J, Norioka N, et al
    Predictors of endothelial function improvement in patients with mild hypertriglyceridemia without evidence of coronary artery disease treated with purified eicosapentaenoic acid.
    Atherosclerosis. 2020;309:27-32.
    PubMed     Abstract available


  47. GULIZIA MM, Maggioni AP, Abrignani MG, Bilato C, et al
    Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study.
    Atherosclerosis. 2020;308:32-38.
    PubMed     Abstract available


  48. PASTA A, Cremonini AL, Formisano E, Fresa R, et al
    Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies.
    Atherosclerosis. 2020;308:6-14.
    PubMed     Abstract available


  49. STOCK J
    Familial hypercholesterolemia: An urgent public health priority.
    Atherosclerosis. 2020 Jul 18. pii: S0021-9150(20)30351.
    PubMed    


  50. GALLO A, Charriere S, Vimont A, Chapman MJ, et al
    SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia.
    Atherosclerosis. 2020;306:41-49.
    PubMed     Abstract available


    May 2020
  51. LAU P, Soubeyrand S, Hegele RA, Lagace TA, et al
    Molecular mechanism linking a novel PCSK9 copy number variant to severe hypercholesterolemia.
    Atherosclerosis. 2020;304:39-43.
    PubMed     Abstract available


  52. STOCK JK
    Homozygous familial hypercholesterolaemia: New hope for getting patients to goal?
    Atherosclerosis. 2020 May 25. pii: S0021-9150(20)30230.
    PubMed    


  53. ADEMI Z, Norman R, Pang J, Liew D, et al
    Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
    Atherosclerosis. 2020;304:1-8.
    PubMed     Abstract available


  54. TSIMIKAS S, Stroes ESG
    The dedicated "Lp(a) clinic": A concept whose time has arrived?
    Atherosclerosis. 2020;300:1-9.
    PubMed     Abstract available


    March 2020
  55. PANG J, Abraham A, Vargas-Garcia C, Bates TR, et al
    An age-matched computed tomography angiographic study of coronary atherosclerotic plaques in patients with familial hypercholesterolaemia.
    Atherosclerosis. 2020;298:52-57.
    PubMed     Abstract available


  56. ADINOLFI LE, Petta S, Fracanzani AL, Coppola C, et al
    Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study.
    Atherosclerosis. 2020;296:40-47.
    PubMed     Abstract available


  57. CHO DH, Song IS, Choi J, Gwon JG, et al
    Risk of peripheral arterial disease in patients with periodontitis: A nationwide, population-based, matched cohort study.
    Atherosclerosis. 2020;297:96-101.
    PubMed     Abstract available


    February 2020
  58. LUIRINK IK, Hutten BA, Greber-Platzer S, Kolovou GD, et al
    Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry.
    Atherosclerosis. 2020;299:24-31.
    PubMed     Abstract available


  59. NORDESTGAARD BG, Langlois MR, Langsted A, Chapman MJ, et al
    Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM.
    Atherosclerosis. 2020;294:46-61.
    PubMed     Abstract available


    January 2020
  60. CHIU YW, Wu CS, Chen PC, Wei YC, et al
    Risk of acute mesenteric ischemia in patients with diabetes: A population-based cohort study in Taiwan.
    Atherosclerosis. 2020;296:18-24.
    PubMed     Abstract available


  61. KOSKINEN JS, Kyto V, Juonala M, Viikari JSA, et al
    Childhood risk factors and carotid atherosclerotic plaque in adulthood: The Cardiovascular Risk in Young Finns Study.
    Atherosclerosis. 2020;293:18-25.
    PubMed     Abstract available


  62. SON DH, Lee HS, Lee YJ
    Association between serum carbohydrate antigen 19-9 levels and leukoaraiosis in middle-aged and older adults: A cross-sectional study.
    Atherosclerosis. 2020;292:188-192.
    PubMed     Abstract available


  63. MASUDA D, Miyata Y, Matsui S, Yamashita S, et al
    Omega-3 fatty acid ethyl esters improve low-density lipoprotein subclasses without increasing low-density lipoprotein-cholesterol levels: A phase 4, randomized study.
    Atherosclerosis. 2020;292:163-170.
    PubMed     Abstract available


  64. MAEDA N, Funahashi T, Matsuzawa Y, Shimomura I, et al
    Adiponectin, a unique adipocyte-derived factor beyond hormones.
    Atherosclerosis. 2020;292:1-9.
    PubMed     Abstract available


    November 2019
  65. MULDER JWCM, Galema-Boers AMH, de Jong-Verweij LM, Hazelzet JA, et al
    The development and first results of a health-related outcomes set in familial hypercholesterolemia (FH) patients: Knowledge is health.
    Atherosclerosis. 2019;293:11-17.
    PubMed     Abstract available


  66. WALD DS, Bestwick JP
    Reaching detection targets in familial hypercholesterolaemia: Comparison of identification strategies.
    Atherosclerosis. 2019;293:57-61.
    PubMed     Abstract available


  67. LAMIQUIZ-MONEO I, Restrepo-Cordoba MA, Mateo-Gallego R, Bea AM, et al
    Predicted pathogenic mutations in STAP1 are not associated with clinically defined familial hypercholesterolemia.
    Atherosclerosis. 2019;292:143-151.
    PubMed     Abstract available


  68. RAMASWAMI U, Futema M, Bogsrud MP, Holven KB, et al
    Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.
    Atherosclerosis. 2019;292:178-187.
    PubMed     Abstract available


    October 2019
  69. RAMOS R, Masana L, Comas-Cufi M, Garcia-Gil M, et al
    Derivation and validation of SIDIAP-FHP score: A new risk model predicting cardiovascular disease in familial hypercholesterolemia phenotype.
    Atherosclerosis. 2019;292:42-51.
    PubMed     Abstract available


  70. CAO YX, Jin JL, Guo YL, Sun D, et al
    Baseline and on-statin treatment lipoprotein(a) levels for predicting cardiovascular events in patients with familial hypercholesterolemia.
    Atherosclerosis. 2019;291:27-33.
    PubMed     Abstract available


    September 2019
  71. STOCK J
    First insights from the EAS familial hypercholesterolaemia collaboration registry: FH is still underdiagnosed and undertreated.
    Atherosclerosis. 2019 Sep 28. pii: S0021-9150(19)31502.
    PubMed    


  72. LEON-ACUNA A, Torres-Pena JD, Alcala-Diaz JF, Vals-Delgado C, et al
    Lifestyle factors modulate postprandial hypertriglyceridemia: From the CORDIOPREV study.
    Atherosclerosis. 2019;290:118-124.
    PubMed     Abstract available


  73. RAMASWAMI U, Humphries SE, Priestley-Barnham L, Green P, et al
    Current management of children and young people with heterozygous familial hypercholesterolaemia - HEART UK statement of care.
    Atherosclerosis. 2019;290:1-8.
    PubMed     Abstract available


    August 2019
  74. DESJARLAIS M, Dussault S, Rivard F, Harel S, et al
    Forced expression of microRNA-146b reduces TRAF6-dependent inflammation and improves ischemia-induced neovascularization in hypercholesterolemic conditions.
    Atherosclerosis. 2019;289:73-84.
    PubMed     Abstract available


  75. HORI M, Ohta N, Takahashi A, Masuda H, et al
    Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients.
    Atherosclerosis. 2019;289:101-108.
    PubMed     Abstract available


  76. DUELL PB, Gidding SS, Andersen RL, Knickelbine T, et al
    Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry.
    Atherosclerosis. 2019;289:85-93.
    PubMed     Abstract available


    July 2019
  77. ANHOLM C, Kumarathurai P, Pedersen LR, Samkani A, et al
    Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
    Atherosclerosis. 2019;288:60-66.
    PubMed     Abstract available


  78. LANGSTED A, Vedel-Krogh S, Kobylecki CJ, Nordestgaard BG, et al
    Reply to: "Seasonal variations of lipid profiles in a French cohort".
    Atherosclerosis. 2019;286:184-186.
    PubMed    


  79. NADIF R, Goldberg S, Gourmelen J, Ozguler A, et al
    Seasonal variations of lipid profiles in a French cohort.
    Atherosclerosis. 2019;286:181-183.
    PubMed    


    June 2019
  80. MASANA L, Ibarretxe D, Rodriguez-Borjabad C, Plana N, et al
    Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain.
    Atherosclerosis. 2019;287:89-92.
    PubMed     Abstract available


  81. DYRBUS K, Gasior M, Desperak P, Osadnik T, et al
    The prevalence and management of familial hypercholesterolemia in patients with acute coronary syndrome in the Polish tertiary centre: Results from the TERCET registry with 19,781 individuals.
    Atherosclerosis. 2019;288:33-41.
    PubMed     Abstract available


  82. WISLOFF T, Mundal LJ, Retterstol K, Igland J, et al
    Economic evaluation of lipid lowering with PCSK9 inhibitors in patients with familial hypercholesterolemia: Methodological aspects.
    Atherosclerosis. 2019;287:140-146.
    PubMed     Abstract available


    May 2019
  83. IYEN B, Qureshi N, Kai J, Akyea RK, et al
    Risk of cardiovascular disease outcomes in primary care subjects with familial hypercholesterolaemia: A cohort study.
    Atherosclerosis. 2019;287:8-15.
    PubMed     Abstract available


  84. PEREZ DE ISLA L, Ray KK, Watts GF, Santos RD, et al
    Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2019;286:40-45.
    PubMed     Abstract available


    April 2019
  85. LUIRINK IK, Kuipers IM, Hutten BA, Planken RN, et al
    Coronary computed tomography angiography and echocardiography in children with homozygous familial hypercholesterolemia.
    Atherosclerosis. 2019;285:87-92.
    PubMed     Abstract available


  86. ALOTHMAN L, Genest J
    Chylomicrons: When you can't direct the wind, adjust the sail.
    Atherosclerosis. 2019;283:121-123.
    PubMed    


    March 2019
  87. MIRAMONTES-GONZALEZ JP, Usategui-Martin R, Perez de Isla L, Alonso R, et al
    VEGFR2 and OPG genes modify the risk of subclinical coronary atherosclerosis in patients with familial hypercholesterolemia.
    Atherosclerosis. 2019;285:17-22.
    PubMed     Abstract available


  88. HARADA-SHIBA M
    How much further do we need to decrease LDL cholesterol levels in heterozygous familial hypercholesterolemia?
    Atherosclerosis. 2019 Mar 9. pii: S0021-9150(19)30121.
    PubMed    


    February 2019
  89. CHEMELLO K, Martin C, Lambert G
    PCSK9 inhibition for autosomal recessive hypercholesterolemia.
    Atherosclerosis. 2019 Feb 23. pii: S0021-9150(19)30091.
    PubMed    


  90. PEREZ-CALAHORRA S, Laclaustra M, Marco-Benedi V, Lamiquiz-Moneo I, et al
    Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia.
    Atherosclerosis. 2019 Feb 12. pii: S0021-9150(19)30081.
    PubMed     Abstract available


    January 2019
  91. RODRIGUEZ-JIMENEZ C, Gomez-Coronado D, Frias Vargas M, Cerrato F, et al
    A new variant (c.1A>G) in LDLRAP1 causing autosomal recessive hypercholesterolemia: Characterization of the defect and response to PCSK9 inhibition.
    Atherosclerosis. 2019 Jan 25. pii: S0021-9150(19)30023.
    PubMed     Abstract available


  92. YAN Y, He F, Li Z, Xu R, et al
    The important role of apolipoprotein A-II in ezetimibe driven reduction of high cholesterol diet-induced atherosclerosis.
    Atherosclerosis. 2019;280:99-108.
    PubMed     Abstract available


  93. XIAO P, Huang T, Yan Y, Zhao X, et al
    Performance of gender- and age-specific cut-points versus NCEP pediatric cutpoints in dyslipidemia screening among Chinese children.
    Atherosclerosis. 2019;280:37-44.
    PubMed     Abstract available


    December 2018
  94. WAKE M, Oh A, Onishi Y, Guelfucci F, et al
    Adherence and persistence to hyperlipidemia medications in patients with atherosclerotic cardiovascular disease and those with diabetes mellitus based on administrative claims data in Japan.
    Atherosclerosis. 2018;282:19-28.
    PubMed     Abstract available


  95. SANTOS RD, Watts GF
    Simon Broome confirms that the IAS definition of severe familial hypercholesterolemia predicts coronary mortality in patients with FH.
    Atherosclerosis. 2018 Dec 22. pii: S0021-9150(18)31544.
    PubMed    


  96. VEDEL-KROGH S, Kobylecki CJ, Nordestgaard BG, Langsted A, et al
    The Christmas holidays are immediately followed by a period of hypercholesterolemia.
    Atherosclerosis. 2018;281:121-127.
    PubMed     Abstract available


  97. GUO J, Gao Y, Li X, He Y, et al
    Systematic prediction of familial hypercholesterolemia caused by low-density lipoprotein receptor missense mutations.
    Atherosclerosis. 2018;281:1-8.
    PubMed     Abstract available


  98. VUORIO A, Watts GF, Kovanen PT
    Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2018;281:25-30.
    PubMed     Abstract available


  99. LUNEGOVA OS, Mirrakhimov EM
    A familial hypercholesterolemia week in Kyrgyzstan: The joint scientific and practical symposium with the European Atherosclerosis Society (EAS), the International Atherosclerosis Society (IAS) and the Kyrgyz Society of Cardiology (KSC).
    Atherosclerosis. 2018 Dec 3. pii: S0021-9150(18)31511.
    PubMed    


    November 2018
  100. SORAN H, Adam S, Durrington PN
    Reply to: "Comments on 'Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk' ".
    Atherosclerosis. 2018 Nov 28. pii: S0021-9150(18)31508.
    PubMed    


  101. KORDONOURI O, Lange K, Boettcher I, Christoph J, et al
    New approach for detection of LDL-hypercholesterolemia in the pediatric population: The Fr1dolin-Trial in Lower Saxony, Germany.
    Atherosclerosis. 2018;280:85-91.
    PubMed     Abstract available


  102. PIRRO M, Francisci D, Bianconi V, Schiaroli E, et al
    NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial.
    Atherosclerosis. 2018;280:51-57.
    PubMed     Abstract available


  103. SHAH SR
    Comments on "Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk".
    Atherosclerosis. 2018 Nov 13. pii: S0021-9150(18)31476.
    PubMed    


  104. HUMPHRIES SE, Cooper JA, Capps N, Durrington PN, et al
    Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register.
    Atherosclerosis. 2018 Nov 12. pii: S0021-9150(18)31469.
    PubMed     Abstract available


  105. REESKAMP LF, Kastelein JJP, Moriarty PM, Duell PB, et al
    Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2018;280:109-117.
    PubMed     Abstract available


  106. BOJANIN D, Vekic J, Milenkovic T, Vukovic R, et al
    Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control.
    Atherosclerosis. 2018;280:14-20.
    PubMed     Abstract available


  107. LUIJTEN J, van Greevenbroek MMJ, Schaper NC, Meex SJR, et al
    Incidence of cardiovascular disease in familial combined hyperlipidemia: A 15-year follow-up study.
    Atherosclerosis. 2018;280:1-6.
    PubMed     Abstract available


    October 2018
  108. ALHABABI D, Zayed H
    Spectrum of mutations of familial hypercholesterolemia in the 22 Arab countries.
    Atherosclerosis. 2018;279:62-72.
    PubMed     Abstract available


  109. SHEK A, Alieva R, Kurbanov R, Hoshimov S, et al
    Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle.
    Atherosclerosis. 2018;277:524-529.
    PubMed     Abstract available


  110. MEHTA R, Martagon AJ, Galan Ramirez GA, Gonzalez Retana G, et al
    The development of the Mexican Familial Hypercholesterolemia (FH) National Registry.
    Atherosclerosis. 2018;277:517-523.
    PubMed     Abstract available


  111. AZRAII AB, Ramli AS, Ismail Z, Abdul-Razak S, et al
    Knowledge, awareness and practice regarding familial hypercholesterolaemia among primary care physicians in Malaysia: The importance of professional training.
    Atherosclerosis. 2018;277:508-516.
    PubMed     Abstract available


  112. BOTHA TC, Pilcher GJ, Wolmarans K, Blom DJ, et al
    Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies.
    Atherosclerosis. 2018;277:502-507.
    PubMed     Abstract available


  113. HAGGER MS, Hardcastle SJ, Hu M, Kwok S, et al
    Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia.
    Atherosclerosis. 2018;277:493-501.
    PubMed     Abstract available


  114. RAAL FJ, Hovingh GK, Catapano AL
    Familial hypercholesterolemia treatments: Guidelines and new therapies.
    Atherosclerosis. 2018;277:483-492.
    PubMed     Abstract available


  115. AFANASIEVA OI, Ezhov MV, Razova OA, Afanasieva MI, et al
    Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Atherosclerosis. 2018;277:477-482.
    PubMed     Abstract available


  116. PANG J, David Marais A, Blom DJ, Brice BC, et al
    Heterozygous familial hypercholesterolaemia in specialist centres in South Africa, Australia and Brazil: Importance of early detection and lifestyle advice.
    Atherosclerosis. 2018;277:470-476.
    PubMed     Abstract available


  117. SOUTO AC, Miname MH, Fukushima J, Jannes CE, et al
    Health related quality of life in individuals at high risk for familial hypercholesterolemia undergoing genetic cascade screening in Brazil.
    Atherosclerosis. 2018;277:464-469.
    PubMed     Abstract available


  118. FUTEMA M, Bourbon M, Williams M, Humphries SE, et al
    Clinical utility of the polygenic LDL-C SNP score in familial hypercholesterolemia.
    Atherosclerosis. 2018;277:457-463.
    PubMed     Abstract available


  119. ALVES AC, Benito-Vicente A, Medeiros AM, Reeves K, et al
    Further evidence of novel APOB mutations as a cause of familial hypercholesterolaemia.
    Atherosclerosis. 2018;277:448-456.
    PubMed     Abstract available


  120. HSIUNG YC, Lin PC, Chen CS, Tung YC, et al
    Identification of a novel LDLR disease-causing variant using capture-based next-generation sequencing screening of familial hypercholesterolemia patients in Taiwan.
    Atherosclerosis. 2018;277:440-447.
    PubMed     Abstract available


  121. LOPEZ G, Bernal LM, Gelvez N, Gomez LF, et al
    Mutational analysis of the LDLR gene in a cohort of Colombian families with familial hypercholesterolemia.
    Atherosclerosis. 2018;277:434-439.
    PubMed     Abstract available


  122. ALNOURI F, Athar M, Al-Allaf FA, Abduljaleel Z, et al
    Novel combined variants of LDLR and LDLRAP1 genes causing severe familial hypercholesterolemia.
    Atherosclerosis. 2018;277:425-433.
    PubMed     Abstract available


  123. BRUNHAM LR, Ruel I, Khoury E, Hegele RA, et al
    Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry.
    Atherosclerosis. 2018;277:419-424.
    PubMed     Abstract available


  124. PETRULIONIENE Z, Gargalskaite U, Kutkiene S, Staigyte J, et al
    Establishing a national screening programme for familial hypercholesterolaemia in Lithuania.
    Atherosclerosis. 2018;277:407-412.
    PubMed     Abstract available


  125. BRETT T, Qureshi N, Gidding S, Watts GF, et al
    Screening for familial hypercholesterolaemia in primary care: Time for general practice to play its part.
    Atherosclerosis. 2018;277:399-406.
    PubMed     Abstract available


  126. TRUONG TH, Kim NT, Nguyen MNT, Pang J, et al
    Homozygous familial hypercholesterolaemia in Vietnam: Case series, genetics and cascade testing of families.
    Atherosclerosis. 2018;277:392-398.
    PubMed     Abstract available


  127. GROSELJ U, Kovac J, Sustar U, Mlinaric M, et al
    Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review.
    Atherosclerosis. 2018;277:383-391.
    PubMed     Abstract available


  128. PAYNE J, Williams S, Maxwell D, Pariente MT, et al
    Familial hypercholesterolaemia patient support groups and advocacy: A multinational perspective.
    Atherosclerosis. 2018;277:377-382.
    PubMed     Abstract available


  129. DESCAMPS OS, Van Caenegem O, Hermans MP, Balligand JL, et al
    A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial Hypercholesterolaemia STrategy).
    Atherosclerosis. 2018;277:369-376.
    PubMed     Abstract available


  130. HARADA-SHIBA M, Ako J, Arai H, Hirayama A, et al
    Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: Results of the EXPLORE-J study.
    Atherosclerosis. 2018;277:362-368.
    PubMed     Abstract available


  131. VRABLIK M, Raslova K, Vohnout B, Blaha V, et al
    Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
    Atherosclerosis. 2018;277:355-361.
    PubMed     Abstract available


  132. LATKOVSKIS G, Saripo V, Gilis D, Nesterovics G, et al
    Latvian registry of familial hypercholesterolemia: The first report of three-year results.
    Atherosclerosis. 2018;277:347-354.
    PubMed     Abstract available


  133. KAYIKCIOGLU M, Tokgozoglu L, Dogan V, Ceyhan C, et al
    What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)?
    Atherosclerosis. 2018;277:341-346.
    PubMed     Abstract available


  134. BELIARD S, Boccara F, Cariou B, Carrie A, et al
    High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
    Atherosclerosis. 2018;277:334-340.
    PubMed     Abstract available


  135. VAN DELDEN XM, Huijgen R, Wolmarans KH, Brice BC, et al
    LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C.
    Atherosclerosis. 2018;277:327-333.
    PubMed     Abstract available


  136. VOHNOUT B, Fabryova L, Klabnik A, Kadurova M, et al
    Treatment pattern of familial hypercholesterolemia in Slovakia: Targets, treatment and obstacles in common practice.
    Atherosclerosis. 2018;277:323-326.
    PubMed     Abstract available


  137. SCHMIDT N, Dressel A, Grammer TB, Gouni-Berthold I, et al
    Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry.
    Atherosclerosis. 2018;277:314-322.
    PubMed     Abstract available


  138. RIZOS CV, Elisaf MS, Skoumas I, Tziomalos K, et al
    Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).
    Atherosclerosis. 2018;277:308-313.
    PubMed     Abstract available


  139. IBARRETXE D, Rodriguez-Borjabad C, Feliu A, Bilbao JA, et al
    Detecting familial hypercholesterolemia earlier in life by actively searching for affected children:The DECOPIN project.
    Atherosclerosis. 2018;278:210-216.
    PubMed     Abstract available


  140. DUMITRESCU A, Mosteoru S, Vinereanu D, Dan GA, et al
    Preliminary data of familial hypercholesterolemia (FH) patients in Romania.
    Atherosclerosis. 2018;277:304-307.
    PubMed     Abstract available


  141. LALIC K, Rajkovic N, Popovic L, Lukac SS, et al
    The effects of 3-year statin therapy and the achievement of LDL cholesterol target values in familial hypercholesterolemia patients: An experience from Serbia.
    Atherosclerosis. 2018;277:298-303.
    PubMed     Abstract available


  142. VALLEJO-VAZ AJ, Ray KK
    Epidemiology of familial hypercholesterolaemia: Community and clinical.
    Atherosclerosis. 2018;277:289-297.
    PubMed     Abstract available


  143. MISEREZ AR, Martin FJ, Spirk D
    DIAgnosis and Management Of familial hypercholesterolemia in a Nationwide Design (DIAMOND-FH): Prevalence in Switzerland, clinical characteristics and the diagnostic value of clinical scores.
    Atherosclerosis. 2018;277:282-288.
    PubMed     Abstract available


  144. POJSKIC L, Pojskic B
    Familial hypercholesterolemia screening program in Bosnia and Herzegovina and cardiovascular morbidity.
    Atherosclerosis. 2018;277:278-281.
    PubMed     Abstract available


  145. HARADA PH, Miname MH, Bensenor IM, Santos RD, et al
    Familial hypercholesterolemia prevalence in an admixed racial society: Sex and race matter. The ELSA-Brasil.
    Atherosclerosis. 2018;277:273-277.
    PubMed     Abstract available


  146. KUTKIENE S, Petrulioniene Z, Laucevicius A, Cerkauskiene R, et al
    Lipid profile evaluation and severe hypercholesterolaemia screening in the middle-aged population according to nationwide primary prevention programme in Lithuania.
    Atherosclerosis. 2018;277:267-272.
    PubMed     Abstract available


  147. PARAGH G, Harangi M, Karanyi Z, Daroczy B, et al
    Identifying patients with familial hypercholesterolemia using data mining methods in the Northern Great Plain region of Hungary.
    Atherosclerosis. 2018;277:262-266.
    PubMed     Abstract available


  148. CORRAL P, Geller AS, Polisecki EY, Lopez GI, et al
    Unusual genetic variants associated with hypercholesterolemia in Argentina.
    Atherosclerosis. 2018;277:256-261.
    PubMed     Abstract available


  149. VALLEJO-VAZ AJ, De Marco M, Stevens CAT, Akram A, et al
    Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).
    Atherosclerosis. 2018;277:234-255.
    PubMed     Abstract available


  150. RAY KK, Watts GF
    Improving the global care of familial hypercholesterolaemia: Starting the ball rolling.
    Atherosclerosis. 2018;277:230-233.
    PubMed    


    September 2018
  151. JUNG KJ, Koh H, Choi Y, Lee SJ, et al
    Familial hypercholesterolemia and atherosclerotic cardiovascular mortality among Korean adults with low levels of serum cholesterol.
    Atherosclerosis. 2018;278:103-109.
    PubMed     Abstract available


  152. FARNIER M, Hovingh GK, Langslet G, Dufour R, et al
    Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program.
    Atherosclerosis. 2018 Sep 1. pii: S0021-9150(18)31345.
    PubMed     Abstract available


    August 2018
  153. CHUNG CM, Lin MS, Liu CH, Lee TH, et al
    Discontinuing or continuing statin following intracerebral hemorrhage from the view of a national cohort study.
    Atherosclerosis. 2018;278:15-22.
    PubMed     Abstract available


  154. SORAN H, Adam S, Durrington PN
    Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.
    Atherosclerosis. 2018;278:135-142.
    PubMed     Abstract available


  155. BELIARD S, Gallo A, Duchene E, Carrie A, et al
    Lipoprotein-apheresis in familial hypercholesterolemia: Long-term patient compliance in a French cohort.
    Atherosclerosis. 2018;277:66-71.
    PubMed     Abstract available


    July 2018
  156. CAO YX, Liu HH, Sun D, Jin JL, et al
    The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia.
    Atherosclerosis. 2018;277:7-14.
    PubMed     Abstract available


    June 2018
  157. MEHTA R, Reyes-Rodriguez E, Yaxmehen Bello-Chavolla O, Guerrero-Diaz AC, et al
    Performance of LDL-C calculated with Martin's formula compared to the Friedewald equation in familial combined hyperlipidemia.
    Atherosclerosis. 2018 Jun 21. pii: S0021-9150(18)31180.
    PubMed     Abstract available


  158. BALLANTYNE CM, Banach M, Mancini GBJ, Lepor NE, et al
    Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
    Atherosclerosis. 2018 Jun 12. pii: S0021-9150(18)30309.
    PubMed     Abstract available


  159. MCKAY AJ, Hogan H, Humphries SE, Marks D, et al
    Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.
    Atherosclerosis. 2018 Jun 4. pii: S0021-9150(18)30290.
    PubMed     Abstract available


    May 2018
  160. SUNG KC, Lee MY, Kim YH, Huh JH, et al
    Obesity and incidence of diabetes: Effect of absence of metabolic syndrome, insulin resistance, inflammation and fatty liver.
    Atherosclerosis. 2018;275:50-57.
    PubMed     Abstract available


  161. CROSLAND P, Maconachie R, Buckner S, McGuire H, et al
    Cost-utility analysis of searching electronic health records and cascade testing to identify and diagnose familial hypercholesterolaemia in England and Wales.
    Atherosclerosis. 2018;275:80-87.
    PubMed     Abstract available


  162. HUMPHRIES SE, Cooper JA, Seed M, Capps N, et al
    Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register.
    Atherosclerosis. 2018;274:41-46.
    PubMed     Abstract available


    April 2018
  163. WENG S, Kai J, Tranter J, Leonardi-Bee J, et al
    Improving identification and management of familial hypercholesterolaemia in primary care: Pre- and post-intervention study.
    Atherosclerosis. 2018;274:54-60.
    PubMed     Abstract available


  164. MACEDONI M, Hovnik T, Plesnik E, Kotnik P, et al
    Metabolic control, ApoE genotypes, and dyslipidemia in children, adolescents and young adults with type 1 diabetes.
    Atherosclerosis. 2018;273:53-58.
    PubMed     Abstract available


    March 2018
  165. WAKE M, Onishi Y, Guelfucci F, Oh A, et al
    Treatment patterns in hyperlipidaemia patients based on administrative claim databases in Japan.
    Atherosclerosis. 2018;272:145-152.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dyslipidemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: